Can Novo, Lilly Take Credit for U.S. Obesity Rate Decline?
Trending Stocks This Week as Strong Jobs Report Underscore Resilience of U.S. Economy
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Looking Into Danaher's Recent Short Interest
EU Regulators Reviewing Safety of Finasteride, Dutasteride
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
Johnson & Johnson Halts Mid-stage Study for Dengue Antiviral
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Thermo Fisher Plant Making Astra/ Sanofi RSV Drug Reportedly Breached FDA Rules
WHO Approves First Mpox Diagnostic Test for Emergency Use
US regulators said eli lilly and co's weight loss miracle drug is no longer in short supply, with 'substitute' manufacturer Hims & Hers plunging more than 10% during trading.
FDA stated that eli lilly and co's two exenatide-containing GLP-1 injection Zepbound and Mounjaro have been in short supply since 2022 due to increased demand, but the shortage issue is now resolved. Industry organizations say that FDA's determination equals to pharmacies stopping the allocation and distribution of generic versions of the two drugs.
Demystifying Merck & Co: Insights From 8 Analyst Reviews
Wells Fargo's 'Core' Stocks: GOOGL, HD, KO, and More
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
Eli Lilly Analyst Ratings
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
Merck & Co Analyst Ratings
Comparing AbbVie With Industry Competitors In Biotechnology Industry